
David Feifel MD PhD
Psychopharmacology, Psychosomatic Medicine
Physician
Join to View Full Profile
3252 Holiday CtSte 112La Jolla, CA 92037
Phone+1 858-412-4130
Fax+1 858-412-5088
Dr. Feifel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Diego) Medical CenterResidency, Psychiatry, 1992 - 1995
University of Toronto Faculty of MedicineClass of 1991
Certifications & Licensure
CA State Medical License 1992 - 2026
American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes Start of enrollment: 2006 Dec 01
- Oxytocin Add on Study for Stable Schizophrenic Patients Start of enrollment: 2008 Mar 01
- Oxytocin Add-on Study for Stable Anxiety Patients Start of enrollment: 2009 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), ...Guy M Goodwin, Scott T Aaronson, Oscar Alvarez, Robin Carhart-Harris, Jamie Chai-Rees
Journal of Affective Disorders. 2025-10-10 - 3 citationsResults From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder.Guy M Goodwin, Ania Nowakowska, Merve Atli, Boadie W Dunlop, David Feifel
The Journal of Clinical Psychiatry. 2025-03-03 - 10 citationsThe role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.Guy M Goodwin, Scott T Aaronson, Oscar Alvarez, Robin Carhart-Harris, Jamie Chai-Rees
Journal of Affective Disorders. 2025-03-01
Press Mentions
Study: Single Dose of LSD Provides Lasting Anxiety ReliefSeptember 8th, 2025
Single Dose of LSD Relieves Anxiety and Depression for Months, Study FindsSeptember 5th, 2025
'One and Done' Dose of LSD Keeps Anxiety at BaySeptember 5th, 2025- Join now to see all
Grant Support
- Neurotensin-1 Receptor As A Therapeutic Target For SchizophreniaNational Institute Of Mental Health2009–2012
- 1/2-Anti-Psychotic Effects Of OxytocinNational Institute Of Mental Health2011
- A Novel Animal Model Of Relevance To SchizophreniaNational Institute Of Mental Health2005–2009
- Antipsychotic-Like Drug Effects Of NeurotensinNational Institute Of Mental Health2002–2004
- Olanzapine + Devalproex VS Placebo + DevalproexNational Center For Research Resources2000–2002
External Links
- Kadima Neuropsychiatry Institutehttp://www.kadimanp.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









